Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the provided transcript. Debt levels have reduced during the quarter with finance costs declining from INR45 crores in Q1 FY26 to INR25 crores in Q1 FY27. The company is targeting becoming a debt-free company from FY28 onwards. Incremental capex planned for NSU segment is modest (INR5-20 crores) and not expected to require large borrowing. Business restructuring (de-merger) is progressing with NCLT approval, aiming for clearer focus and potentially attracting investors specific to consumer or B2B businesses. No explicit statement

Any current/future capex/capital investment/strategic investment?

For the NSU (Nutraceuticals and Specialty Units) segment, the planned capex for the current year is modest, approximately INR 5-20 crores, focusing on incremental and modular expansions rather than large-scale investments. No major large-scale plant investments (INR 400-500 crores) are expected within the next 2 years. Long-term aspiration includes growing the NSU business to INR 600-700 crores by 2030 with improving profitability. New technologies and carbon-smart innovations are being explored but are not yet mature for capital allocation. In renewable materials and performance chemi

Future growth expectations in sales/revenue/volumes?

India Glycols expects a healthy double-digit growth in the potable spirits segment (FY27), driven by deeper penetration in core states and new offerings in deluxe whiskey, rum, and semi-premium vodka segments. Aim to double volume from FY26 levels with premiumization leading to revenue growth outpacing volume growth. Project EBITDA for potable spirits to exceed INR 500 crores in FY27 and target INR 1,000 crores within 4-5 years. The IMFL segment is expected to contribute over 30% of potable spirits revenue. The Ennature Bio Pharma segment aims for INR 130-150 crores EBITDA in 4-5 years, driven

Future growth expectations in earnings/operating earnings/profits/EPS?

India Glycols aims to deliver an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already achieved in Q1. Potable Spirits segment targets doubling of volume from last year, driven by deeper market penetration and premium product launches. The company aspires to achieve EBITDA exceeding INR 1,000 crores in the next 4-5 years, potentially becoming one of the top five alco-bev companies in India. Ennature Bio Pharma targets an EBITDA of INR 130-150 crores within 4-5 years, supported by new acquisitions, nutraceutical launches, and nicotine business expansion. Chemicals business ex

India GlycolsQ1 FY27Beverages

India Glycols Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹311.3P/E: 6.6Market Cap: ₹2.1K CrSector: Beverages

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

India Glycols expects a healthy double-digit growth in the potable spirits segment (FY27), driven by deeper penetration in core states and new offerings in deluxe whiskey, rum, and semi-premium vodka segments.
Aim to double volume from FY26 levels with premiumization leading to revenue growth outpacing volume growth.
Project EBITDA for potable spirits to exceed INR 500 crores in FY27 and target INR 1,000 crores within 4-5 years.
The IMFL segment is expected to contribute over 30% of potable spirits revenue.
The Ennature Bio Pharma segment aims for INR 130-150 crores EBITDA in 4-5 years, driven by growth in nicotine business and nutraceutical launches.
Chemicals business to grow steadily with expansion in bio-based specialty chemicals and performance chemicals.
NSU (New Specialties Unit) business aims to grow from INR 150 crores this year to INR 600-700 crores in 4-5 years with modest capex.

Margin guidance

India Glycols aims to deliver an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already achieved in Q1.
Potable Spirits segment targets doubling of volume from last year, driven by deeper market penetration and premium product launches.
The company aspires to achieve EBITDA exceeding INR 1,000 crores in the next 4-5 years, potentially becoming one of the top five alco-bev companies in India.
Ennature Bio Pharma targets an EBITDA of INR 130-150 crores within 4-5 years, supported by new acquisitions, nutraceutical launches, and nicotine business expansion.
Chemicals business expected to grow with innovations and new performance chemicals contributing to margins, aspiring for gross margins near 30% in 5-6 years.
Overall focus on premiumization and geographical expansion, with inorganic growth expected from new brands and states.
Aim to become a debt-free company by FY28, supporting profitable, sustained growth.

See what India Glycols management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of new fundraising through debt or equity in the provided transcript.
Debt levels have reduced during the quarter with finance costs declining from INR45 crores in Q1 FY26 to INR25 crores in Q1 FY27.
The company is targeting becoming a debt-free company from FY28 onwards.
Incremental capex planned for NSU segment is modest (INR5-20 crores) and not expected to require large borrowing.
Business restructuring (de-merger) is progressing with NCLT approval, aiming for clearer focus and potentially attracting investors specific to consumer or B2B businesses.
No explicit statement regarding raising fresh equity or debt funding in the near term.

Order book

The transcript of India Glycols Limited's Q1 FY27 Earnings Conference Call does not explicitly provide details on the current or expected order book or pending orders. However, relevant insights include: - Ennature Bio Pharma reported a strong order pipeline, supported by new customer acquisitions and nutraceutical launches. - The nicotine business capacity expansion and sales growth indicate increasing demand. - There is continued focus on strengthening product portfolios and market penetration, which may imply a growing order book. - The joint venture (JV) business is performing well with increasing revenues and profitability. - No specific quantitative details on order book size or pending orders were disclosed in the call. For precise order book or pending order figures, further direct communication with the company is recommended.

See what India Glycols management said on order book — free account, 30 seconds.

Capex plans

For the NSU (Nutraceuticals and Specialty Units) segment, the planned capex for the current year is modest, approximately INR 5-20 crores, focusing on incremental and modular expansions rather than large-scale investments.
No major large-scale plant investments (INR 400-500 crores) are expected within the next 2 years.
Long-term aspiration includes growing the NSU business to INR 600-700 crores by 2030 with improving profitability.
New technologies and carbon-smart innovations are being explored but are not yet mature for capital allocation.
In renewable materials and performance chemicals, moderate investments are planned, supported by innovation and partnerships.
Acquisition and geographic expansion in the Potable Spirits segment will likely involve some investments, but specific capex figures were not disclosed.

Track India Glycols — get its next earnings analysis in your feed

How does India Glycols rank vs peers in Beverages?

Pro feature

ThisIndia Glycols

See where India Glycols sits in BeveragesSee which companies these are, and every other name in the sector.Open rankings

How does India Glycols rank in Beverages?

Compare India Glycols against every Beverages company (Q1 FY27) on revenue, margins and earnings-call signals.

View Beverages leaderboard →

What India Glycols's management said in earlier quarters

Earlier calls (7)

Others in Beverages this season

Associated Alcohols & Breweries (Q2 FY27)
Q2FY27 Net Revenue from Operations: Rs 2,716 Mn, up 7% YoY (Page 8) . Key investor presentation takeaways from Associated Alcohols & Breweries Ltd's Q2 FY27 inv
Piccadily Agro (Q2 FY27)
Year-on-Year Change in Revenue from Operations:** Increase of INR 4,518.81 lakhs (~19.4% growth) . Key investor presentation takeaways from Piccadily Agro Indus
Ravikumar Distll (Q2 FY27)
19.3% decrease) . Key results statement takeaways from Ravikumar Distilleries Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sula Vineyards (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 145.4 Cr, up 4% YoY . Key investor presentation takeaways from Sula Vineyards Ltd's Q2 FY27 investor presentation — and how

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →